1. Home
  2. KURA vs TMCI Comparison

KURA vs TMCI Comparison

Compare KURA & TMCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KURA
  • TMCI
  • Stock Information
  • Founded
  • KURA 2014
  • TMCI 2014
  • Country
  • KURA United States
  • TMCI United States
  • Employees
  • KURA N/A
  • TMCI N/A
  • Industry
  • KURA Biotechnology: Biological Products (No Diagnostic Substances)
  • TMCI Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Sector
  • KURA Health Care
  • TMCI Health Care
  • Exchange
  • KURA Nasdaq
  • TMCI Nasdaq
  • Market Cap
  • KURA 611.7M
  • TMCI 649.1M
  • IPO Year
  • KURA N/A
  • TMCI 2021
  • Fundamental
  • Price
  • KURA $8.25
  • TMCI $9.37
  • Analyst Decision
  • KURA Strong Buy
  • TMCI Hold
  • Analyst Count
  • KURA 10
  • TMCI 8
  • Target Price
  • KURA $27.13
  • TMCI $8.84
  • AVG Volume (30 Days)
  • KURA 1.8M
  • TMCI 413.1K
  • Earning Date
  • KURA 02-26-2025
  • TMCI 02-27-2025
  • Dividend Yield
  • KURA N/A
  • TMCI N/A
  • EPS Growth
  • KURA N/A
  • TMCI N/A
  • EPS
  • KURA N/A
  • TMCI N/A
  • Revenue
  • KURA N/A
  • TMCI $202,861,000.00
  • Revenue This Year
  • KURA N/A
  • TMCI $13.27
  • Revenue Next Year
  • KURA $280.91
  • TMCI $8.61
  • P/E Ratio
  • KURA N/A
  • TMCI N/A
  • Revenue Growth
  • KURA N/A
  • TMCI 16.14
  • 52 Week Low
  • KURA $6.98
  • TMCI $3.92
  • 52 Week High
  • KURA $24.17
  • TMCI $14.82
  • Technical
  • Relative Strength Index (RSI)
  • KURA 47.12
  • TMCI 47.42
  • Support Level
  • KURA $7.87
  • TMCI $9.69
  • Resistance Level
  • KURA $8.55
  • TMCI $10.30
  • Average True Range (ATR)
  • KURA 0.55
  • TMCI 0.45
  • MACD
  • KURA 0.03
  • TMCI -0.16
  • Stochastic Oscillator
  • KURA 43.48
  • TMCI 3.40

About KURA Kura Oncology Inc.

Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.

About TMCI Treace Medical Concepts Inc.

Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers, and hospitals.

Share on Social Networks: